Exploring New Technology To Personalize Therapy Beyond Standard Approaches

The Appendix Cancer PMP Research Foundation (ACPMP) is pleased to announce an opportunity for patients to participate in testing a potentially groundbreaking technology. Travera's mission is to bring hope to cancer patients who are running out of therapeutic options. Travera is offering its 2-day Rapid Therapy Selection™ test to patients with appendiceal and peritoneal cancers free of charge to help in their efforts to establish more treatment options and outcomes data.

Travera is doing work in appendiceal cancer as part of its larger focus on other gastrointestinal cancers and gynecologic cancers. They are assisting oncologists in selecting treatments for their patients using a revolutionary cancer therapy selection test that predicts which cancer drugs are most likely to be effective for each cancer patient, a potentially valuable tool for patients with rare or advanced diseases. This novel technology invented at MIT has overcome the problems that have prevented the many previous generations of therapy selection tests from being effective in clinical practice.

If you’d like to learn more about testing and potentially initiate the testing process prior to the webinar, you can follow this link to learn more. Here is a brief description of the test to get you started:    • When Standard Cancer Therapy Fails: T...  .